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Abstract
Some epigenetic modifier proteins have become validated clinical targets. With a few small molecule inhibitors already
approved by national health administrations and many more in the pharmaceutical industry pipelines, there is a need
for technologies that can promote full comprehension of the molecular action of these drugs. Proteomics, with its
relatively unbiased nature, can contribute to a thorough understanding of the complexity of the megadalton
complexes, which write, read and erase the histone code, and it can help study the on-target and off-target effect of
the drugs designed to modulate their action. This review on the one hand gathers the published affinity probes able
to decipher small molecule targets and off-targets in a close-to-native environment. These are small molecule
analogues of epigenetic drugs conceived as protein target enrichment tools after they have engaged them in cells or
lysates. Such probes, which have been designed for deacetylases, bromodomains, demethylases, and
methyltransferases not only enrich their direct protein targets but also their stable interactors, which can be identified
by mass spectrometry. Hence, they constitute a tool to study the epigenetic complexes together with other
techniques also reviewed here: immunoaffinity purification with antibodies against native protein complex constituents
or epitope tags, affinity matrices designed to bind recombinantly tagged protein, and enrichment of the complexes
using histone tail peptides as baits. We expect that this toolbox will be adopted by more and more researchers willing
to harness the spectacular advances in mass spectrometry to the epigenetic field.
Keywords: Target deconvolution, Complex identification, Affinity matrix, Photo-cross-linking, Affinity purification,
Immunoaffinity purification
Background
Proteomics has proven to be a reliable ally to study
drug-protein interactions and protein-protein interac-
tions for the last 20 years [1]. Substantial progress in the
mass spectrometry techniques now allows to measure
accurately and quantitatively the proteins contained in
complex samples. Advances in the technology allow
shorter measurement times while digging deeper in the
proteomes. Hydrolases and kinases have been the great
beneficiaries of past efforts to characterize sub-proteomes
and their inhibitors [2, 3]. But they are not the only ones.
The field of epigenetic proteomics could develop further
as it accompanies the thriving phase of epigenetic drug
discovery endeavors and successes [4–6] outlined
throughout this special issue.
Chemical proteomics methods to identify
epigenetic drug targets and off-targets
Among the contributions made by proteomics to the
field of epigenetics [5], chemical proteomics [7] has
emerged as a solid methodology to decipher small mol-
ecule targets and off-targets via so-called compound
pulldowns. These consist of the enrichment of the sub-
proteome that is bound by a small molecule in a com-
plex lysate or even directly in cells and generally mass
spectrometry readout. Because of unspecific binding or
cross-linking, the sub-proteome enriched by inactive
molecules can be compared as a control. However, a bet-
ter strategy is to compete with the free small molecule,
preferably in a dose-dependent fashion, where the fit of
the curves will help determine the reality of the newly
found targets. Additionally, such a competition assay will
give EC50s, which can be converted to Kd values if a
pulldown of the drug vehicle control pulldown flow-
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through is performed to assess the depletion of each
protein [8].
It has to be noted that the foremost advantage of the
chemical proteomics approach is that the assay can be
performed in disease-relevant systems, where the pro-
teins are close to the native state, contain the relevant
PTMs, and are engulfed in their complexes.
The ability of chemical proteomics approaches to
characterize a comprehensive spectrum of targets and
off-targets in cells or tissues is of fundamental import-
ance for a thorough understanding of compound prom-
iscuity or polypharmacology [9] in these systems, i.e., the
bothersome or welcome fact that a single drug often en-
gages multiple targets, some of which are unknown dur-
ing its discovery. Chemical proteomics therefore serves
as a key link between diverse drug responses on a cellu-
lar or organismal level and a compound’s selectivity that
is being increasingly scrutinized in the emerging field of
systems pharmacology [10]—in epigenetics or beyond.
For example, Maleszewska et al. observed that, at low
concentration, the HDAC2 inhibitor valproic acid in-
creased H4 deacetylation in C6 glioma cells. This
contradictory effect was hypothesized to be due to vari-
ous known off-targets of valproic acid [11]. Moreover,
the compound LY294002, which has been used as a
PI3K inhibitor in more than 5000 PubMed-referenced
publications, has clear PI3K-independent effects in
cells. A chemical proteomics study recently revealed
that the so far incomprehensible effects of this tool in-
hibitor (shared by a PI3K-inactive structural analogue)
most likely result from activity against bromodomain
proteins [12].
This may serve as an example for a widely accepted
chemical proteomics strategy to distinguish members of
the targeted protein complex from mistakenly captured
off-targets, namely the use of orthogonal probes. Due to
their chemically different structures, orthogonal probes
are expected to not only share specificity for the targeted
protein complex but also have different sets of off-
targets [13]. Vice versa, this approach can also be a valu-
able tool to purposely screen for off-targets of known in-
hibitors to elucidate mechanisms behind complicated
phenotypic effects.
The term activity-based protein profiling (ABPP) has
been generalized to any kind of pulldowns featuring
some covalent bond between the small molecule of
interest and the proteins it is bound to. This wording
was meaningful when it was coined for the study of hy-
drolases: the probe was effectively hijacking the chemical
mechanism of the enzymatic reaction, since the mole-
cules were designed to react analogous to a substrate. It
is however questionable if a binding followed by proxim-
ity driven photo-cross-linking can be assimilated to ac-
tivity. Indeed, it carries with it the confusion of activity
assay versus binding assay. As recently in the kinase
field, activity profiling was claimed to be achieved with
affinity matrices made out of type I kinase inhibitors be-
fore this conclusion was recently proven to be a seldom
case, it appears important to be somewhat careful with
this shift of meaning [14]. We are therefore choosing to
avoid the ABPP acronym in the review, when the mole-
cules described are not hijacking the mechanism of the
proteins. Most of the probes are binding in the active
pocket of the enzymes without being analogues of reac-
tion intermediates and are therefore affinity probes.
Some strategies make full use of a strong affinity that
allow the maintenance of the interaction long-enough so
that the interactors can be identified after washing.
Other strategies feature a subsequent step of cross-
linking, which bears the advantage of covalent linkage
and the possibility of locating the binding event. These
strategies, however, also give rise to unspecific cross-
linking where the kinetics play a crucial role.
The conceptually simplest approach to decipher the
targets of a drug is to immobilize a linkable analogue of
the molecule on a solid matrix and to proceed to the en-
richment of the binders out of a cell or tissue lysate. This
approach is incompatible with the in cellulo binding that
is addressable by a molecule equipped with a handle
allowing post-lysis pulldowns. In this case, a cross-linker
can also be added. It has to be noted that any modification
of the initial molecule can impair binding, that the bulk
and length of the linker matters, and that cross-linking
can be relatively low-yielding and unspecific [15]. Hence,
we propose to distinguish (Fig. 1) between the:
– Small molecule ligand immobilized on a solid
matrix. Different solid matrices can be envisioned,
the most common being Sepharose beads or
magnetic beads.
– Small molecule ligand functionalized with an
enrichment handle. This enrichment handle can be
a biotin moiety, allowing subsequent enrichment
with a streptavidin matrix. It can also be a
biorthogonal tag allowing for further enrichment
using click reactions [16, 17].
– Small molecule ligand functionalized with a cross-
linking group and an enrichment handle. The cross-
linking group are very often photoreactive functional-
ities such as benzophenones, aryl azides, or diazirines
[18, 19].
Deacetylase enrichment probes
Since the HDAC inhibitor Vorinostat (aka SAHA) has
been the epigenetic drug the most studied by chemical
proteomics, we shall begin by describing the various re-
ported approaches using linkable analogues of this mol-
ecule. They constitute a good overview of what is possible
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in the field: all the approaches described above (Fig. 1)
have indeed been successfully used for the identification
of Vorinostat targets.
A team of researchers in Cellzome immobilized a link-
able analogue of Vorinostat (p-aminomethyl Vorinostat)
and an analogue of Givinostat on Sepharose beads to ob-
tain an affinity matrix able to enrich HDAC1, 2, 3, 6, 8,
and 10 out of K562 cell extracts. They then set the free
Vorinostat and 15 other HDAC inhibitors (PCI-34051,
MC-1293, valproic acid, PCI-24781, Romidepsin, Tacedi-
naline, Entinostat, BML-210, Mocetinostat, Scriptaid,
Belinostat, Apicidin, Panobinostat, Dacinostat, Trichos-
tatin A) to compete for binding with the beads using six
different drug concentrations. The proteins eluted from
the beads were labeled with TMT and measured simul-
taneously to obtain the dose-response curves in one
mass spectrometry measurement. Kdapps for all the
drug-native protein interactions could hence be ob-
tained, establishing the selectivity profiles of these inhib-
itors. The authors then adapted the chemical proteomics
method to high-throughput replacing mass spectrometry
readout by multiplexed fluorescent antibody on “dot
blot” arrays. This allowed them to profile a small library
of molecules in the lysate of Jurkat and Ramos cells for
HDAC1, 2, 3, and 6 binding. Bufexamac, an anti-
inflammatory drug with unknown target, was identified
as preferentially inhibiting HDAC6 in this screen, and its
profile was further assessed by the original chemical pro-
teomics profiling assay revealing its selectivity for
HDAC6 and 10 in the 10 μM range [20]. The immobi-
lized Vorinostat was later also used to profile dual
HDAC/BET inhibitor binding to class I and IIb HDACs
[21]. Lu et al. also immobilized Vorinostat using a p-
amino Vorinostat analogue and enriched binders out of
Hela cell lines which they compared to the proteins
enriched by control beads with a mass spectrometry
readout [22]. Salisbury and Cravatt introduced in 2007
an analogue (SAHA-BPyne) of Vorinostat featuring a
benzophenone moiety for UV induced cross-linking and
a terminal alkyne that was used to click on azido-
rhodamine for gel visualization or onto an azide contain-
ing biotin analogue for enrichment with avidin beads.
HDAC1, 2, 3, and 6 could be identified as targets after
on-bead digestion and mass spectrometry readout in
some cancer cell line lysates. The probe could also be
used in cellulo. No other direct binder of Vorinostat was
identified by the method [23]. Others created their cap-
ture tool based on Vorinostat and featuring a biotin tag
Fig. 1 Affinity probes for the identification of drug targets by chemical proteomics strategies. An analogue of the small molecule is synthesized
that a is covalently attached to a solid matrix or b possesses an enrichment handle or c possesses a cross-linking moiety and an
enrichment handle
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and an aryltrifluoromethyldiazirine moiety attached by
extended hydrophilic linkers. They identified HDAC1, 2,
3, and 6 as well as 13 other proteins as specifically
enriched by the probe out of HepG2 cell lysate, among
which they confirmed ISOC2 as a direct binder [24].
Petukhov and coworkers also created a Vorinostat de-
rivative with a 3-azido-5-azidomethylbenzyloxy moiety
appended to the 4-position of the Vorinostat phenyl,
allowing UV cross-linking with the 3-azido group and
enrichment by click chemistry with the 5-azidomethyl
group and biotin-alkyne/avidin agarose. However, this
tool was not used to enrich targets out of complex bio-
logical samples but to identify binding poses of Vorino-
stat in HDAC8 by studying the cross-linked peptides
[25]. Another photo-cross-linking Vorinostat analogue
was designed by Luo and coworkers featuring a benzote-
trazole equipped with a terminal alkyne handle. Upon ir-
radiation, the probe could cross-link the carboxylic acid
moiety of a HDAC1 and HDAC2 glutamic acid residue
adjacent to the binding site of the drug in HepG2 cell
lysate and live cells. The alkyne handle was used for fur-
ther click reaction for visualization (rhodamine-azide) or
enrichment with streptavidin beads (biotin-azide) before
western blot readout. The modification site was identi-
fied by mass spectrometry using purified proteins, pre-
venting the identification of off-targets [26]. A recent
approach used the chloroalkane capture tag as an en-
richment handle which can be efficiently and very
quickly bound to the commercial Promega HaloTag
magnetic particles [27]. The Promega authors compared
Vorinostat-choloroalkane to Vorinostat-biotin for in cel-
lulo target engagement and found the first to have a 2.3-
fold reduced potency compared to untagged Vorinostat
while the second had a 16-fold reduced potency, an ef-
fect which was due to biotin interference with the bind-
ing, as proven by a BRET assay. This difference
translated in the targets identified by pulldowns
followed by elution with free Vorinostat, where the
Vorinostat-chloroalkane HaloTag strategy allowed to
show binding to HDAC1, 2, 3, 6, 8, and 10 whereas
the Vorinostat-biotin strategy only allowed to identify
HDAC6. The in cellulo target engagement of
Vorinostat-chloroalkane and kinetics of the HaloTag
capture proved to be excellent and thus avoided the
use of cross-linking moieties to stabilize the interac-
tions. In addition to these targets, the thiol diox-
ygenase ADO and the serine/threonine phosphatase
CPPED1 could be identified as targets. The authors
confirmed that Vorinostat is a direct inhibitor of
these two metallo enzyme by BRET competition assay.
Also the conversion of cysteamine to hypotaurine was
inhibited when purified ADO was incubated with Vor-
inostat, possibly shedding light on the reported effi-
cacy of Vorinostat in Huntington’s disease.
Trapoxin with its epoxyketone moiety has been shown
to be an irreversible inhibitor. This should have ham-
pered the use of a simple pulldown and elution strategy
with a solid matrix functionalized with a Trapoxin
analogue. The first designed strategy was, therefore, fea-
turing a disulfide containing linker that would have been
cleaved in the elution step. However, this approach was
reported as unsuccessful whereas a non-cleavable linker
allowed to elute HDAC1. The authors had, therefore, to
conclude that this inhibitor is a covalent but reversible
inhibitor [28, 29]. This matrix is the only one reported
here that qualifies as ABPP since the epoxide is believed
to react in mimicry to the acetyl carried by the lysine the
enzyme is removing. Already in this seminal work per-
formed two decades ago, which led to the identification
of mammalian HDAC1 by Edman degradation, the
immobilized Trapoxin matrix was competed not only
with Trapoxin but also with Trichostatin, allowing to es-
tablish that these two inhibitors of histone deacetylation
have a common binding site (or that, at least, the bind-
ing of one impairs the binding of the other one by struc-
tural rearrangement of the proteins).
Salisbury and Cravatt took their SAHA-BPyne further
and in another publication compared it to other HDAC
probes featuring benzophenone and terminal alkynes at-
tached in various positions to different HDAC binders
or potential binders. These included probes inspired by
CI99. However, they found their initial SAHA-BPyne to
be the most interesting tool [30]. The Gottesfeld group
reported that two of their pimelic diphenylamid series
featuring an anilinine zinc binding group were amenable
to proteomics experiments. They were complemented
by a BPyne moiety for the purpose and used in the bio-
logical context of Friedreich’s ataxia. Whereas HDAC3 is
the preferred target over HDAC1 and 2, the authors
could only evidence its presence by western blot while
HDAC1 and 2 were clearly identified in the mass spec-
trometry readout [31, 32]. Chen and coworkers have re-
ported the synthesis of a probe featuring a BPyne moiety
as a tool to decipher the targets of cinnamic hydroxamic
acids in the frame of an anti-hepatitis C virus agent drug
discovery program. Since they report that the parent
para-trifluoromethyl cinnamic hydroxamic acid has sub-
micromolar activity for HDAC6 and 8, it is likely that
the probe will also enrich these HDACs and maybe
others in their future work [33]. Albrow and coworkers
created a series of photoaffinity probes based on Panda-
costat, TFMK, and TMP269, featuring a benzophenone
photo-cross-linker and either a biotin or an alkyne en-
richment handle. Whereas no derivative of TMP269
could retain the HDAC4 potency of the parent com-
pound, one TFMK-BPyne analogue retained potency and
selectivity to remain a class IIa selective molecule and,
impressively, one Pandacostat-BPyne proved to be even
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superior to Pandacostat in its pan-HDAC potency against
recombinant HDACs. Using HeLa lysates, however, com-
parison of the enriched proteins with the Pandacostat-BP-
biotin immobilized on streptavidin-coated agarose with
and without competing Pandacostat-BPyne could only
identify HDAC 1, 2, 3, 6, and 8 as targets, failing to
achieve the elusive class IIa enrichment and underscoring
the difficulty to translate results obtained with truncated
versions of the class IIa HDACs [34].
Among histone deacetylases, Sirtuins (also known as
class III HDACs) are quite distinct since unlike all other
HDACs which use Zn2+ as a cofactor, they need NAD+
to act as deacetylating enzymes and play their part in
epigenetic regulation [35]. Hence, other HDACs inhibi-
tors cannot promiscuously bind to the Sirtuin class, and
dedicated capture tools have to be designed in order to
profile their inhibitors. Sauve and coworkers designed an
ABPP strategy using a N-thioacetyl-lysine peptide which,
under catalysis of the sirtuin, displaces the nicotinamide
of an analogue of NAD+ to form a stalled thioimidate.
They designed the NAD+ analogue to contain an
aminooxy biorthogonal tag (linker positioned at the 6-
position of the adenine) which could be reacted with an
aldehyde moiety tethered to the biotin enrichment han-
dle further used to enrich the covalently attached pro-
teins with streptavidin functionalized agarose beads [36].
Jung and coworkers designed a biotin functionalized
Sirt2 selective inhibitor which exploits an isotype specific
pocket arising from a major rearrangement of the active
site upon inhibitor binding. Pulling down with magnetic
streptavidin beads, they proved the selectivity of enrich-
ment of Sirt2 over Sirt1 out of a native HL60 cell culture
using western blot as a readout [37]. Dose-dependent
competition with free drugs and mass-spec readout is
still to come in order to evaluate by chemical proteomics
the possible off-targets of their new class of inhibitors.
Bromodomain probes
Using HepG2 hepatocyte cell line containing an apolipo-
protein A1 luciferase reporter, researchers at GSK identi-
fied a benzodiazepine able to potently induce this gene.
In order to deconvolute the target of the new class of
compounds they had developed, a linkable analogue of
the best molecule (I-BET762; I-BET; GSK525762) was
synthesized. They compared the proteins retained by an
agarose matrix functionalized with this linkable analogue
(I-BET721; N-I-BET; GSK923121) to the proteins
retained on a control matrix with the inactive enantio-
mer (GSK525768). Addition of the free drug would elute
the retained proteins which were identified by mass spec-
trometry readout to be BRD2, BRD3, and BRD4. The
matrix was further used to show that the drug interacts
with the bromodomain containing N-terminal (1–473)
truncate of BRD2 and not the C-terminal truncate
(473–801) [38]. With this matrix in hand, GSK has
since complemented their characterization of new
BET inhibitors by chemical proteomics assays. An I-
BET762 dose-response competitive assay in HL60 cell lys-
ate allowed to generate EC50 values for the three inhibited
BET proteins [39]. Immunobloting allowed to visualize
that the new analogue I-BET151 was also preventing
BRD4 to be enriched by the beads in HL60, MV4;11, and
RS4;11 cell extracts [39]. I-BET295, DUAL946, and two
other BET inhibitors (all 10 μM) were used to compete
for binding with the matrix in HL60 extracts showing the
binding to BRD2, 3, and 4. DUAL946 and another candi-
date were then profiled in a dose-response manner to ob-
tain Kdapps [21].
Yao’s group prepared analogues of the benzodiazep-
ine GW841819X functionalized with a diazirine
photo-cross-linker and three different enrichment
handles (an alkyne moiety and two cyclopropenes).
After evaluation of the probes, two of them were used for
in situ labeling of HepG2 cells with and without JQ1 as a
competitor. The labeled proteins were clicked with azido-
biotin or tetrazin-biotin before enrichment with avidin
agarose beads. Comparing the overlaps and the back-
ground obtained with negative control probes, they estab-
lished a list of 48 higher-confidence potential targets of
JQ1. Among these, they confirmed by western blot that
DDB1 and RAD23B were not enriched when JQ1 was co-
incubated with the probes [40].
Of note is the synthesis of a biotinylated version of JQ1
to investigate the genome-wide binding of this bromodo-
main inhibitor to the BET bromodomain family members
BRD2, BRD3, and BRD4 in MM1.S multiple myeloma
cells (Chem-seq). After binding of the biotinylated JQ1 to
its targets in cells or lysates, the chromatin-associated pro-
teins were cross-linked to DNA with formaldehyde, which
allowed to enrich with streptavidin beads the DNA frag-
ments bound to the drug-target complex. Subsequent se-
quencing of these DNA fragments established the binding
loci of the drug target [41].
Researchers in Pfizer discovered tropolone methyl
ether derivatives to be CREBBP and BRD4 submicromo-
lar binders. Interestingly, this acetyl lysine mimicking
moiety is an inherent photo-cross-linker and the authors
utilized this property: they appended an alkyne to their
lead structure and after incubation with a BRD4 spiked
K562 cell lysate under UV irradiaton, they could click
and enrich BRD4 as proven by western blot. JQ1 was
proven to compete to a certain extent. Endogenous
BRD4 could, however, not be enriched, probably due to
the fact that tropolones also cross-link tubulin [42].
Bromodomain binders can also be found among kinase
inhibitors. A Cellzome team immobilized the commonly
used PI3K probe LY294002 as well as LY303511, a PI3K
inactive compound acting similarly in a number of studies
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independently of PIK3 pathway. Comparison of the pro-
teins of HL60 cell extracts enriched by the two matrices
evidenced a large overlap with PI3Ks, PRKDC, mTOR,
and CK2 as clear exceptions. Notably, BRD2, BRD3, and
BRD4 were the most abundant proteins when performing
pulldowns with both the matrices. Unique targets of
LY294002 such as the PI3Ks could be confirmed by dose
response competitive assays of LY294002 and LY303511
against the immobilized LY294002 matrix. All three BETs
were found to be inhibited similarly by both molecules.
Corrected by the depletion factor, the apparent binding
constants were around 1 μM, only two to four times more
than the constants for the PI3Ks, and can possibly explain
the PI3K independent effects observed [12]. To decipher
if the drug is binding to the bromodomains or to a pre-
viously suggested kinase domain, the authors set up
dose-response experiments with MgATP and I-BET151,
a previously developed BET inhibitor, in competition
with the immobilized LY294002 matrix. ATP did not
prevent the matrix to bind BRD4, whereas the known
BET inhibitor did, in a dose-dependent manner with an
IC50 of 160 nM as evidenced by immunoblotting, estab-
lishing bromodomains as the binding site. A surprise
arose when the inhibitor was used in a competition
assay against the I-BET121 matrix described earlier or
against the immobilized drug: the found IC50s readout
by western blot was 40 times higher when the I-
BET121 matrix was used but was similar to the one
found when an immobilized H4K5acK8acK12ac matrix
was used. This was consistent with LY294002 being se-
lective for only one of the two bromodomains of the
BETs while I-BET121 is not. To confirm this hypoth-
esis, the team used yet another chemical proteomics
approach which they combined with cellular biology:
they compared the binding of the immobilized inhibi-
tors to flag-tagged BRD4 isoform C point mutants over-
expressed in HEK293T cells. Whereas the I-BET121
matrix could enrich wild-type Y97A and Y390A but not
Y97/390A proteins, neither the LY303511 nor the N-
LY294002 matrix could enrich the Y97A mutant but
still enriched the wild-type and Y390A mutants. As Y97A
affects the first bromodomain and Y390A the second bro-
modomain, this constitutes a piece of evidence that
LY294002/LY303511 acts as a true histone H4 mimetic
only binding to the first bromodomain of BETs [12].
In the light of this work and two independent reports of
several X-ray structures of kinase inhibitors bound to bro-
modomains [43, 44], we here wish to report that many
matrices designed to enrich kinases also enrich bromodo-
main containing proteins. Analyzing the raw data generated
by Kuster and coworkers to characterize such matrices [8,
14, 45–48], it appeared that Cpd2, linkable SB203580,
VI16743, and to a lesser extent Bisindolylmaleimide X,
CTx0294885 and linkable Dasatinib are able to enrich
BRD2, 3, and 4. Interestingly, the JAK enriching matrix 3b
[48] could enrich ATAD2 in all three replicates. Further
characterization will be necessary to define their binding
modes and usability in competition experiments.
We have noted how compounds have been profiled
with the repertoire of bromodomains enriched by an af-
finity matrix made out of a linkable molecule other than
the one to study. This evidently creates blind spots and
the results cannot be seen as a full profile. To alleviate
the need to synthesize at least one linkable analogue for
every drug (the presence of the linker can also create
blind spots), akin to what has been done for kinases with
Kinobeads [8, 49] or MIBs [50], a combination of affinity
probes has been developed to profile in a more unbiased
way potential bromodomain inhibitors and gain insight
in their selectivity. Named “bromospheres” such a
sepharose-based matrix enriching 19 bromodomain con-
taining proteins has been used to profile three new
ATAD2 inhibitors in HuT-78 mixed chromatin and nu-
clear extracts. After TMT labeling and mass spectrom-
etry readout, dose-response curves of the molecules for
the endogenous proteins were obtained. However, the
structures of the three molecules forming this matrix
have yet to be revealed [51].
Demethylase probes
The discoverers of GSK-J1 validated the target engage-
ment and selectivity of the drug using a chemical proteo-
mics approach. They created a linkable analogue (GSK-J3)
which they immobilized on Sepharose beads. This matrix
was able to capture Flag-tagged JMJD3 and Flag-tagged
UTX from transiently transfected HEK-293 cells and
could efficiently be competed with 100 mM GSK-J1. HL-
60 cells were treated with phorbol myristate acetate to
trigger the expression of JMJD3, which could be enriched
specifically by the matrix. Competition with 100 mM
GSK-J1 produced the disappearance of the western blot
band for endogenous JMJD3, while mass spectrometry
readout concluded to the exquisite selectivity of the drug
[52]. Bush et al. created a set of tripodal (pharmacophore,
cross-linking moiety, and enrichment handle) IOX1 (5-
carboxy-8-hydroxyquinoline) derivatives by Ugi four-
component reaction and evaluated their efficiency in
cross-linking isolated EGLN1 [53]. Since IOX1 is a broad
spectrum 2-oxoglutarate oxygenase inhibitor with submi-
cromolar activity against a range of histone demethylases
[54], these probes could serve in competition assays to as-
sess the selectivity of new inhibitors. Pushing further the
idea of immobilizing unspecific 2-oxoglutarate-dependent
dioxygenase binders, Joberty et al. created five affinity
probes that they immobilized on Sepharose beads. Two of
these molecules were oxoglutarate analogues, another
probe was based on a known bipyridyl scaffold while the
two others were nicotinic acid derivatives that the authors
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identified in a screen. With the obtained matrices, they
could enrich 40 different dioxygenase enzymes from hu-
man cells out of the around 60 known such proteins, as
identified by mass spectrometry. The discovery of such
matrices allowed for the study of natural cofactor oxoglu-
tarate and oncometabolites binding across the panel of
enriched enzymes (notably 18 Jumonji-type proteins) by
competitive pulldown assays/mass spectrometry readout.
Moreover, with such a technological platform in place,
profiling of small molecules inhibitors were performed.
The Jumonji demethylase inhibitors JHDM-I1, GSK-J1, a
pyrido [3,4-d]pyrimidin-4(3H)-one derivative, a 3-amino-
pyridine-4-carboxylate derivative and a 3-cyano-pyrazolo-
pyrimidinone derivative were profiled and were shown to
exhibit varying potencies and selectivities for this family of
proteins [55]. Hence, the chemical proteomics approach
with mixed affinity matrix was proven to be a suitable tool
to study the affinity and selectivity of existing and future
demethylase inhibitors.
Methyltransferase probes
Jin and coworkers reported the synthesis of a biotin deri-
vatized analogue of UNC0638, an inhibitor of the lysine
methyltransferase G9a, which could be used to coat
streptavidin magnetic beads. This affinity matrix was
then used to enrich the target protein out of HEK293T
whole cell extracts. Binding to G9a could be inhibited by
competition with the free drug as proven by western blot
analysis [56]. In another report the authors disclose the
immobilization on Sepharose beads of the aminopropyl
analogue of UNC0638. This affinity matrix was used in
combination with the SILAC technique (stable isotope
labeling by amino acids in cell culture) to determine the
differential abundance of more than 2000 proteins
enriched from nuclear extracts of BMDMs under differ-
ent inflammatory states [57]. Based on a panel selectivity
study for UNC0638 [58], they considered that the probe
only bound G9a as a substrate competitive ligand and
used the obtained list of proteins as potential G9a inter-
actors. These two affinity matrices should be useable to
generate dose response binding curves in competition
experiments, first to confirm the excellent selectivity of
UNC0638 and then to also validate the complexes.
Indeed in chemical proteomics pulldowns, many
targets are enriched together with the complexes they
are engulfed in. When performing competition experi-
ments with a dilution series of a drug, typical dose-
response curves of the direct targets of the drug are
to be observed and also matching curves for the pro-
teins which are co-enriched as member of stable
complexes. This feature can be put to fruition to
study epigenetic complexes as will be detailed in the
next chapter.
Beyond the study of the isolated modulators:
tools to study complexes
Epigenetic modifications are carried out in a dynamic
manner and are executed by multi-protein complexes,
which can be described as writers that add posttransla-
tional modifications (PTMs), erasers that remove them,
and readers that provide PTM-dependent docking sites
for additional functionally relevant protein complexes
[59]. Even though many proteins involved in each of the
tasks have been identified, epigenetic regulation occurs
on the level of more complex protein interactions, which
has gained rising interest during the past decade [60].
The study of protein complex composition has benefited
from the combination of affinity purification (e.g., tan-
dem affinity purification (TAP)) with mass spectrometry
based proteomics [61]. Mass spectrometry has proven to
be a useful tool not only for protein discovery but also
to complement biochemistry based functional studies
[62]. Hereinafter, we will describe proteomic strategies
used to discover and characterize histone-modifying pro-
tein complexes. We will highlight the fact that in epigen-
etics, more than in other fields of research, it is protein
complexes rather than single gene product enzymes that
carry out the functions of writers, erasers, or readers.
Because of this high level of complexity, typically several
different proteomic methods need to be combined, in
order to elucidate protein complex composition or the
mechanism of action of drugs. These approaches include
co-purifications via immobilized drugs, antibodies
against native protein complex constituents, affinity
matrices against epitope tags, or other recombinant tags
and bait peptides (Fig. 2; Table 1).
Chemoproteomics: pulldowns with immobilized drugs
and other approaches
With the trapoxin matrix described earlier, Taunton et
al. in 1996 were able to capture and identify not only
HDAC1 for the first time but also RBBP4 (RbAp48)
which was also lost from the matrix when trapoxin or
trichostatin were set to compete for binding. Further ex-
periments allowed them to indicate that HDAC1 was
the enzymatic subunit while RBBP4 was serving a func-
tion of histone targeting [28]. Bantscheff et al. made use
of their affinity matrix (vide infra) to also study the
HDAC complex subunits that could be co-enriched and
co-inhibited with free drugs. The authors characterized
at least four different known HDAC complexes, includ-
ing CoREST, NuRD, Sin3, and NCoR, scaffolded by
ELM-SANT domain proteins as specific targets for sub-
sets of 16 HDACi. In addition to the bead-immobilized
drug, a competing inhibitor was added to the incubation
mixture prior to affinity purification. Subsequent quanti-
tative mass spectrometry-based analysis enabled the de-
termination of HDAC complex specific dissociation
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constants for the various drugs. Bidirectional hierarch-
ical clustering of dissociation constants against more
than 500 proteins and the 16 HDACi suggested the ex-
istence of an additional unknown mitotic deacetylase
complex (MiDAC). Moreover, the study showed a high
selectivity of aminobenzamide for the HDAC3-NCor
complex and little binding to the HDAC Sin3 complex
[20]. In an extension of the chemical proteomics strategy,
the matrix was used to evaluate the binding kinetics of
hydroxamate and aminobenzamide inhibitors to the
HDAC megadalton repressor complexes. Most remark-
ably, it was shown that, whereas hydroxamate inhibitors
establish an equilibrium within second with the targets, it
takes aminobenzamide inhibitors minutes for HDAC3/
NcoR complex and hours for most of the complexes.
Strikingly, it was also found that, for this scaffold,
HDAC1/2 are not accessible when part of the Sin3 com-
plex [63]. The Yates and Gottesfeld laboratories teamed
up to use the pimelic diphenylamid probe described earl-
ier for the study of HDAC complexes in Friedreich’s ataxia
patient iPSC-derived stem cells. After their pulldowns,
they simply compared the set of proteins enriched by the
probe [31] to the interactome of all HDACs as defined by
Cristea and coworkers in a study that we describe later in
this review [64]. As mentioned earlier, Cravatt and co-
workers synthesized a set of HDACi-BPyne. One of the
goals was to change the position of the cross-linker, in
order to reach proteins interacting with the HDACs the
Fig. 2 Strategies to capture histone-modifying complexes. These approaches include co-purifications via small molecule affinity probes, antibodies
against native protein compounds, antibodies against epitope tags, non-epitope tag/tag binder couple, and bait peptides mimicking histone tails
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probes were binding to. SAHA-BPyne could itself enrich
CoREST, MBD3, MTA1, MTA2, and p66b and the au-
thors could hence compare the abundance of the com-
plexes across a range of cell lines [23, 30]. Similarly, the
group of Petukhov extended their range of HDAC probes
featuring a 3-azido-5-azidomethylbenzyloxy moiety
(which we described earlier for Vorinostat) and studied by
western blot which of these “nanoruler” probes could
cross-link SMRT while binding to HDAC3. They con-
cluded that in the physiologically relevant conditions of
HT29 cell lysates, SMRT is bound to HDAC3 in another
conformation than in the X-ray structure [65].
This chemoproteomic approach is inherently limited
by the availability of potent molecules targeting the pro-
tein complexes of interest as starting point to create
linkable analogues. However, for many enzymes, no in-
hibitor is known or the synthesis of a suitable analogue
appears too tedious. Antibodies can then be an alterna-
tive. Preferentially, they should be an orthogonal tech-
nique used in complement.
Immunoaffinity purification of native protein complexes
Among antibody-based purifications of protein com-
plexes, antibodies can target either native protein sub-
units or recombinant epitope tags. The advantage of
antibodies targeting protein subunits is the ability to
study physiologic complexes with a stoichiometry that is
unaltered by overexpression [66–68].
For example, Liang et al. studied transcription-
regulating complexes by capturing endogenous proteins.
The transcription factors Nanog and Oct-4 are important
for maintaining self-renewal and undifferentiated state in
embryonic stem cells [69]. Immunoaffinity purifications
(IAP) of Nanog and Oct4 from mouse embryonic stem
cells revealed interactions with several repression com-
plexes, including members of the HDAC chromatin re-
modeling complex NuRD and the repressor complex
Sin3A. These interactions are relevant for embryonic cell
fate decisions like self-renewal and pluripotency [70].
IAP when used in combination with chemoproteomics
methods can help to deconvolute data from immobilized
drug pulldowns: The latter often enrich mixtures of mul-
tiple protein complexes that are then co-eluted from the
affinity matrix. For instance, immobilized pan-HDAC
inhibitors affinity-capture all HDAC1-, HDAC2-, or
HDAC3-containing protein complexes simultaneously.
Therefore, proteomic analysis of all co-eluting proteins
is not sufficient for unanimous characterization of indi-
vidual protein complexes. In contrast, when chemopro-
teomics studies like these are complemented with IAPs
using antibodies against known and unique subunits of
single HDAC1, HDAC2, and HDAC3 complexes, e.g.,
antibodies against Sin3A, then comparison to proteins
captured by immobilized HDAC inhibitors enables
characterization of individual HDAC protein complexes
[20]. Moreover, comparison of chemo- and IAP proteo-
mics data can lead to the identification of novel HDAC
protein complexes [20]. Finally, it enables the differenti-
ation of direct HDACi binding targets from HDAC com-
plex members [7].
A similar set of combined chemoproteomics, IAP pro-
teomics, and additional affinity-capture proteomics ex-
periments using compounds targeting the acetyl lysine
recognizing bromodomain and extra terminal (BET)
family of proteins and antibodies against individual BET
complex subunits led to the elucidation of a potentially
new therapeutic option for mixed lineage leukemia
(MLL): Dawson et al. combined immobilized BET in-
hibitor pulldowns with IAPs and pulldowns using acety-
lated histone peptides and revealed association of the
BET proteins BRD3 and BRD4 with the polymerase-
associated factor complex (PAFc) and the super elong-
ation complex (SEC), a key regulator of transcriptional
elongation. Since translocation and fusion of the mll
gene with members of the PAFc or SEC protein com-
plexes has been implicated in leukemogenesis [71, 72],
this newly discovered protein-protein interaction drew
attention to the possible merit of using BET inhibitors
for MLL leukemia treatment [39].
Despite the fact that antibodies raised against moieties
of epigenetic proteins have proven their value, currently
available literature suggests that these are rarely used.
The main reasons may be the high cost and time
requirement of raising antibodies and the frequently un-
satisfying specificity that render them unsuitable for pro-
teomics studies. Depending on the epitope that the
antibody was raised against, antibody binding might also
interfere with relevant protein-protein interactions [73].
Antibody against epitope tags
Epitope tags are short peptide sequences attached to
proteins during cloning and recombinant protein ex-
pression. They are frequently used for antibody-based
detection or affinity (co-) purification purposes. The rep-
ertoire of common epitope tags, including FLAG, HA,
and c-myc tags, has been reviewed elsewhere [74]. The
main advantage of utilizing epitope tags for affinity puri-
fications is the availability of very well characterized high
quality anti-epitope tag antibodies.
For a long time, experimental strategies involving cel-
lular expression of epitope or otherwise tagged proteins
and their incorporation of tagged recombinant proteins
into complexes in cell culture have been hampered by
non-physiological and often poorly reproducible expres-
sion levels and, consequently, undefined stoichiometry.
Many expression vectors that are typically used in mo-
lecular and cell biology, e.g., cytomegalovirus (CMV)
promoters, are designed for high protein expression.
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Very high yield of the tagged bait protein per cell is,
however, not desired in protein complex research, as
many true interacting proteins are expressed at low en-
dogenous levels and thus may be titrated out in the
process. As a consequence, highly overexpressed bait
proteins are often associated with few interacting pro-
teins in low quantities that may evade identification. It
has been recognized many years ago that alternative ex-
pression systems such as retroviral vectors that drive ex-
pression from long terminal repeat promoters may be
beneficial and favor low bait protein expression consist-
ent with more physiological protein complex formation
[66, 75].
In a seminal 2010 study, Vermeulen et al. overcame
this issue of difficult-to-control protein expression and
protein complex stoichiometry by using a bacterial artifi-
cial chromosome (BAC) expression system [76]. BACs
enable the gene expression from endogenous promoters
in the presence of most regulatory genetic elements [77]
or a knock-in of the recombinant protein [78]. They
studied multiple trimethyl lysine reader protein com-
plexes using a method called BAC transgeneOmics.
Trimethyl lysine readers were initially captured using
methylated prey peptides and identified using bottom-up
proteomics. Promising candidates were then expressed
as green fluorescent protein (GFP)-tagged proteins in
HeLa cells. Protein complexes were extracted and puri-
fied in a single step using GFP-affinity resin. SILAC la-
beling enabled the reliable differentiation of specific
binders from cell medium contaminants. For example,
the study identified a double tudor domain in the C-
terminus of Sgf29 as the H3K4me3-binding unit of the
SAGA-complex. Moreover, they found a PWWP domain
as putative H3K36me3 binding motive [76]. BAC-GFP
transgenic HeLa cells have also been used to study the
H3K4me3 reading EMSY complex. The latest quantita-
tive mass spectrometry technology was used to analyze
GFP-pulldowns of different EMSY-subunits. The tran-
scription factor ZNF131 was identified, which recruits
EMSY to active promoters [79].
In the field of epigenetics, epitope tagging has been
the most widely used strategy for analysis of epigenetic
protein complexes:
Proteins of the MYST family are highly conserved his-
tone acetyl transferases (HATs) in eukaryotes, which typ-
ically possess a chromodomain and a zinc finger. One
important member is the HAT HBO1 [80]. Purifications
of MYST complexes revealed a tetrameric structure,
which consists of a scaffold protein core, an ING tumor
suppressor protein, and a catalytic enzyme unit [81]. Co-
IAP FLAG-tagged BRPF1 as bait revealed the for-
mation of novel MYST complexes, whose histone
acetylation specificity depends on the scaffold pro-
tein core. HBO1 in a complex with JADE acetylates
histone H4, whereas HBO1 in a complex with BRPF1
acetylates histone H3 [82].
The polycomb repressive complex 2 (PRC2) is one of
the main histone methyl transferases inducing transcrip-
tional silencing of chromatin. PRC2 consists of three
core proteins: enhancer of zeste 2 (EZH2), embryonic
ectoderm development (EED), and suppressor of zeste
12 homolog (SUZ12) [83]. Shen et al. found that Ezh2
knockout did not abolish H3K27 methylation in mouse
embryonic stem cells. Pulldowns of FLAG- and biotin-
tagged EED from MESCs found the EZH2 homolog
EZH1 in a non-canonical PRC2 complex. EZH1 pre-
serves H3K27 methylation mark on chromatin of
development-related genes in EZH2-deficient cells,
which suggests that EZH1 safeguards the identity of em-
bryonic stem cells [84]. IAP of FLAG-EZH2 from 293F
cells revealed an interaction with Jarid2, a Jumonji C
demethylase domain-containing protein that apparently
lacks enzymatic activity. Jarid2 recruitment to a pro-
moter triggered co-recruitment of PRC2 and increased
methyltransferase activity [85].
Another histone methyl transferase complex is the
MLL/COMPASS group of SET-domain histone methyl-
transferases (SET1/MLL). SET1/MLL and PRC2-
complexes have been shown to often regulate the same
promoter targets [86]. Van Nuland et al. performed a
quantitative study on human SET1/MLL histone methyl-
transferase complexes. The expression of GFP-tagged
subunits of COMPASS-like complexes gave insights to
the stoichiometry of different SET1/MLL1 complexes. In
addition, Bap18-GFP bacterial artificial chromosomes
were used for the expression of a core component of the
NURF chromatin remodeling complex. Bap18 pulldowns
revealed that Dpy30 protein is not only a core COM-
PASS subunit but also a subunit of NURF [87].
In addition, class III HDAC complexes, i.e., sirtuin
protein complexes, have been studied by co-IAP of epi-
tope tagged proteins. Purification of the FLAG-tagged
histone deacetylase SIRT1 found an interaction with the
tumor suppressor DBC1 [88]. SIRT1 has been shown to
deacetylate p53 to promote cell survival [89]. Inhibition
of SIRT1 by DBC1 initiates p53-mediated apoptosis [88].
SIRT1-mediated deacetylation of p53 is stimulated by
the transcription factor Oct4 to maintain pluripotency of
ESCs [90]. Nanog, Sox2, and Oct4 are critical transcrip-
tion factors to maintain self-renewal capacity in embry-
onic stem cells [91]. IAP of epitope tagged Oct4 and
four of its binding transcriptions factors (Sall4, Esrrb,
Dax1, and Tcfcp2l1) from mouse embryonic stem cells,
in turn, revealed the complex interaction network of
Oct4. The interaction of Oct4 and the nucleosome
remodeling deacetylase (NuRD) HDAC complex mem-
ber SALL4 stresses its role in modulating epigenetic
silencing [92].
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Joshi et al. gave a comprehensive overview on the
interactors of the HDAC family. All human HDACs
(HDAC 1–11) were GFP-tagged and co-immunopurified
from CEM-T cells. Among the 200 novel identified inter-
actions, a role of HDAC 11 in snRNP assembly and
RNA processing was found and also the repertoire of
known HDAC1 interacting proteins was expanded.
Moreover, a metabolic labeling strategy was invented to
study protein complex stabilities. For that, light-labeled
GFP-HDAC expressing cells were mixed with heavy-
labeled wild-type cells during co-immunopurification.
The comparison of isotope protein ratios enabled con-
clusions on the exchange ratios of protein complex
members. The approach showed that exchange ratios in
HDAC1 containing complexes are rather slow and
therefore more stable, whereas association of transcrip-
tion factors is less stable [64].
The bromodomain protein Brd4 contains a pTEFb
interaction domain. Binding of Brd4 to pTEFb stimulates
transcriptional activation [93]. A co-purification of HA-
tagged N-terminal domain of Brd4 revealed that the
extraterminal domain of Brd4 recruits different effectors
including NSD3 and JMJD6, which mediates transcrip-
tional activation independent of pTEFb [94].
Mutations in methyl reader PHF6 are associated with
the neurodegenerative disease Börjeson-Forssman-Leh-
mann syndrome as well as with MLL and T-ALL leuke-
mias. PHF6 has been FLAG-tagged and immunoaffinity
purified to identify interacting proteins. The experiment
brought to light an interaction with the NuRD deacetyla-
tion complex and, hence, implicated PHF6 in chromatin
regulation [95].
Recombinant tags other than epitope tags
Aside from epitope tags, two other classes of protein tags
for purification purposes have been extensively used: The
first class consists of proteins (e.g., glutathione-S-
transferase (GST)) or peptides like polyhistidine that bind
to immobilized small molecules. The second class in-
cludes (poly)peptides such as calmodulin binding peptide
or protein A that bind to immobilized proteins such as
calmodulin and immunoglobulin, respectively [96]. In
some cases two such affinity moieties have been combined
in a single expression vector. Such tags have been devel-
oped especially for tandem affinity purification (TAP)
mass spectrometry and are referred to as TAP tags. The
rationale underlying the use of TAP tags is based on the
notion that a single affinity purification step is often not
sufficient to obtain pure protein (complexes). In contrast,
TAP tags enable two-step affinity purifications under “na-
tive” conditions (i.e., pH 7.4 and physiological salt concen-
tration) to reduce unspecific binders. Moreover, the
design of TAP tags aims for low molecular weight
(<20 kDa) to limit interference with protein folding [68].
The classical TAP tag consists of protein A and calmodu-
lin binding peptide (CBP). The linker region between the
two tags contains a rare protease recognition site, which
enables cleaving the CBP-tagged protein off of the IgG-
bound protein A by tobacco edge virus protease [97].
Doyon et al. used a TAP-tagging approach to study
protein complexes containing inhibitor of growth (ING)
proteins of the PHD domain-containing family that are
involved in both tumor suppression and oncogenesis.
They elucidated a central role of ING proteins in regu-
lating chromatin acetylation, as several TAP-tagged
ING-family members were found to associate with pro-
tein complexes involved in histone acetylation and dea-
cetylation [81]. For example, ING2 associates with an
HDAC complex, and its knockdown, has been shown to
suppress cancer, thus identifying ING2 as a potential
anti-cancer drug target [98]. ING4 and ING5 associate
with HAT complexes [81].
The ING1 ortholog YNG1 is a member of the NuA3
histone acetylase complex in yeast. Different laboratories
purified TAP-tagged subunits of the NuA3 complex to
gain insights into its composition, regulation, and func-
tion [99–101]. Purification of TAP-tagged YNG1 found
YNG1 to mediate NuA3 histone acetylation at H3K14.
The pulldown also identified the previously uncharacter-
ized PWWP domain protein Pdp3 as a member of the
NuA3 complex [101]. Studies on the network of Sas3p, a
HAT in the NuA3 complex, using a TAP-tag purification
approach confirmed the association of Pdp3 with the
NuA3 complex [100]. The use of TAP-tagged Pdp3 en-
abled the purification and classification of a NuA3b
complex, which is functionally different from the non-
Pdp3 containing NuA3a complex. This novel NuA3b
complex mediates transcriptional elongation by binding
to H3K36me3 in a Pdp3 regulated manner [99].
The histone methyl transferase SUV420H2 is a mark
for pericentric chromatin. The Angrand laboratory TAP-
tagged SUV420H2 and isolated its interaction partners
from the nuclear extracts of HeLa cells. The group iden-
tified the heterochromatin protein HP1 as a major inter-
action partner of SUV420H2 [102]. In subsequent
publications, the same laboratory studied members of
the HP1 protein family, also referred to as chromobox
homolog (CBX). HP1 isotypes were TAP-tagged and
interacting partners tandem affinity purified. Those pub-
lications focused on the differences in protein complex
composition among the HP1/CBX proteins [103, 104].
PRC1 is a histone methyl and ubiquitin transferase
complex, which belongs with PRC2 to the family of
polycomb group (PcG) complexes. TAP-based proteo-
mics on PRC1 complex members found that the ubiqui-
tin ligases RING1 A/B are members of all PRC1
complexes, whereas composition of the ring finger motif
containing PCGF proteins varies. Six different PRC1
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complexes were defined based on the contained PCGF
protein. Moreover, incorporation of a RING1 binding
protein, RYBP, prevents association of canonical com-
plex members like CBX. Knock down of RYBP revealed
its importance for embryonic stem cell proliferation
[105]. The lysine specific demethylase 1 (LSD1) was the
first discovered histone demethylase [106]. Its isoform
LSD1+8a shows strong expression in neurons. Purifica-
tion of TAP-tagged LSD1+8a from SH-SY5Y neuronal
cell line revealed an interaction with the supervillin pro-
tein (SVIL). SVIL colocalizes with LSD+8a in promoter
regions and functions as a cofactor for LSD+8a-medi-
ated H3K9me2 demethylation [107]. The transcription
factor Snail1 contains a SNAG domain, which shows
structural similarity to histone H3 peptide. Purification
of TAP-tagged Snail1 found an interaction with LSD1.
The interaction of LSD1 with this molecular hook
represses gene expression and results in decreased cell
migration [71].
The bromodomain (BRD) protein ZMYND8 is a mul-
tidomain protein, which contains beside its BRD a plant
homology (PHD) domain and a PWWP domain. Purifi-
cation of SFB-tagged (S-tag, Flag epitope tag, and
streptavidin-binding peptide tag) ZMYND8 found inter-
actions with NuRD and BRAF HDAC complexes, which
are important for promoting homologous recombination
upon DNA damage [108].
Kloet et al. performed quantitative interaction studies on
the NuRD HDAC complex. The group found that in
contrast to the core units, binding to some zinc
finger-containing proteins like SALL4 is salt-sensitive.
Cross-linking MS was performed to identify intermo-
lecular interactions between the methyl-CpG-binding
protein MBD3 and the NuRD complex. Moreover, co-
purifications of His-GFP-MBD3 revealed that the
histone chaperones RBBP4 and RBBP7 dynamically
interact with the MBD3-NuRD complex [109].
A novel NuRD-type chromatin remodeling complex
was identified by Kolla et al. The chromodomain con-
taining protein CHD4 and FOG1 are transcription fac-
tors in the NuRD complex. Pulldown experiments of
GST-FOG1 identified a CHD4 homolog CHD5, which
forms a similar NuRD complex. This novel chromatin
remodeling complex might be important for normal cell
development and tumor suppression [110].
Histone tail peptides as baits
A further approach to capture epigenetic regulating pro-
tein complexes are exposed protein tails, which mimic
the recognition site of protein domains. To study epi-
genetic regulators, the peptides of choice are histone
tails containing different modifications like methyl or
acetyl groups [39, 76, 111].
Vermeulen et al. compared the binding of histone
readers to modified prey peptides using a SILAC ap-
proach. The affinity purification matrix used was immo-
bilized N-terminal histone H3 tails showing different
modifications. Extracts from cells supplied with light
amino acids were exposed to a non-methylated peptide
whereas extracts from heavy-labeled cells were exposed
to a methylated peptide. The experiment identified
TFIID as a H3K4me3 binding protein [112].
Li et al. also studied Histone H3 methyl-lysine binding
proteins using a SILAC approach. Their histone H3 N-
terminal tail probe contained additional chemical modi-
fications including a click chemistry sensitive alkyne
group for avidin tagging as well as a benzophenone
group for UV cross-linking. The approach constitutes
an interface between exposing prey peptides to pro-
tein complexes and chemical tagging of subunits of
the complex. The heavy-labeled cellular extracts were
exposed to a non-methylated histone tail, whereas
heavy-labeled extracts were exposed to a trimethylated
lysine residue. The identification of a new H3K4Me3
binding protein (MORC3) was demonstrated [113]. In
a subsequent publication, it was shown that the use
of diazirine instead of benzophenone as a cross-
linking group yielded a more sensitive probe to cap-
ture H3K4Me3 binding proteins [114].
Zegerman et al. found that methylation at H3K4 pre-
vents the NuRD complex from binding to the tail of H3.
The group exposed N-terminal residues of histone H3
to nuclear extracts. The NuRD complex co-purified with
unmodified histone tails but not with a peptide contain-
ing a trimethylated lysine 4 [115].
A similar approach was used to identify the PHD fin-
ger protein BPTF that specifically binds to H3K4Me3.
BPTF is a subunit of the NURF complex. Therefore, the
finding forms another link between histone modifica-
tions and chromatin remodeling [116].
Unstructured N-terminal tails of histone H3 have also
been used to study protein complexes binding to rarely
studied modifications like crotonylation and phosphoryl-
ation [111, 117, 118].
The Kapoor laboratory studied proteins binding to
phosphorylation at H3T3, using a modified histone H3
tail peptide. The approach identified a phosphorylation-
dependent protein-protein interaction with the phos-
binding protein survivin, which only occurs during
mitosis [111]. Kunowska et al. identified a novel complex
binding the double H3K9me3/S10ph modification by ex-
posing nuclear extracts to respective histone peptides.
The complex integrates members of the chromatin re-
modeling FACT complex [118].
Bao et al. exposed nuclear extracts to histone H3 tail
peptides, which contain a crotonylation mark at lysine 4.
They found that several sirtuins (SIRT1, SIRT2, SIRT3),
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which belong to the HDAC family, possess decrotony-
lase activity [117].
Immobilized histones tail peptides have also been used
to study binding efficacy of epigenetic complexes upon
inhibitor treatment [39, 119, 120].
Conclusions
There is no doubt that proteomics can and will help on
every step of the epigenetic drug discovery effort in the
years to come. Hence, the studies that have been
reviewed here are to be seen as a mere commencement.
We believe that they constitute the surface of what is
possible and that many discoveries using proteomics ap-
proaches lie ahead of us. Exciting developments should
also settle or find their way in the epigenetics field,
expanding the proteomics toolbox to study drug action
and protein complex composition. For instance, the pos-
sibility to photo-cross-link inhibitors to beads without
the need to synthesize linkable analogues is a promising
approach [121] which could render pulldowns a routine
characterization tool after any phenotypic screen. An-
other expansion of the toolbox is an approach based on
the successful combination of cellular thermal shift as-
says (CETSA) and bottom-up proteomics [122, 123].
This innovation, also referred to as thermal proteome
profiling (TPP), makes use of (small molecule) ligand-
induced thermal stabilization of target proteins. When
incorporated into quantitative proteomics workflows, it
can be used for identification of direct and indirect drug
targets in living cells, as was recently demonstrated
using the HDACi panobinostat as a point in case [124].
Recent evidence also suggests that the study of epigen-
etic complexes and their inhibitors by proteomics is not
the prerogative of tandem liquid chromatography mass
spectrometry but that matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry may, especially
when used as an imaging modality, play its part, as dem-
onstrated by Munteanu et al.: they presented a cellular
assay based on whole cell MALDI MS fingerprinting
that enables label-free measurement of cellular potency
and monitoring of drug target engagement of HDACi
(panobinostat) without requiring any enrichment or
sophisticated sample preparation steps [125, 126]. More-
over, MALDI MS imaging can visualize histone modifica-
tions and consequently drug action of histone-modifying
small molecules in a spatially resolved manner, thereby
opening up the door for a fruitful marriage of “omics” and
imaging [125, 127]. Finally, as the boundaries of the epi-
genetics target space remains fuzzy with a complexity be-
yond the currently pursued drug discovery efforts [128],
proteomics has a major role to play. With relatively un-
biased methods, mass spectrometry-based proteomics in-
deed offer new opportunities to identify and characterize
new epigenetics target/inhibitor couples which should find
a much needed translation in the clinic.
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